Leading researchers have contributed state-of-the-art chapters to this overview of high-performance computing in biomedical research. The book includes over 30 pages of color illustrations. Some of the important topics featured in the book include the following:

"This book disseminates knowledge regarding high performance computing for medical applications and bioinformatics"--Provided by publisher.

Leading researchers have contributed state-of-the-art chapters to this overview of high-performance computing in biomedical research. The book includes over 30 pages of color illustrations. Some of the important topics featured in the book include the following:

This volume explores the application of high-performance computing (HPC) technologies to computational drug discovery (CDD) and biomedicine. The first section collects CDD approaches that, together with HPC, can revolutionize and automate drug discovery process, such as knowledge graphs, natural language processing (NLP), Bayesian optimization, automated virtual screening platforms, alchemical free energy workflows, fragment-molecular orbitals (FMO), HPC-adapted molecular dynamic simulation (MD-HPC), and the potential of cloud computing for drug discovery. The second section delves into computational algorithms and workflows for biomedicine, featuring an HPC framework to assess drug-induced arrhythmic risk, digital patient applications relevant to the clinic, virtual human simulations, cellular and whole-body blood flow modeling for stroke treatments, prediction of the femoral bone strength from CT data, and many more subjects. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary software and tools, step-by-step and readily reproducible modeling protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, High Performance Computing for Drug Discovery and Biomedicine allows a diverse audience, including computer scientists, computational and medicinal chemists, biologists, clinicians, pharmacologists and drug designers, to navigate the complex landscape of what is currently possible and to understand the challenges and future directions of HPC-based technologies.

This document contains the transcript of three hearings on the High Speed Performance Computing and High Speed Networking Applications Act of 1993 (H.R. 1757). The hearings were designed to obtain specific suggestions for improvements to the legislation and alternative or additional application areas that should be pursued. Testimony and prepared statements were received from: (1) John H. Gibbons, Office of Science and Technology Policy; (2) Thomas J. Tauke, NYNEX; (3) Robert H. Ewald, Cray Research; (4) W. B. Barker, BBN Communications; (5) Richard F. Rashid, Microsoft; (6) Major R. Owens, House Subcommittee on Select Education and Civil Rights; (7) Don E. Detmer, University of Virginia; (8) Connie Stout, Texas Educational Network; (9) John Masten, New York Public Library; (10) Martin A. Massengale, University of Nebraska; (11) Cynthia H. Braddon, Information Industry Association; (12) Donald A. B. Lindberg, National Coordination Office for HPCC Program; (13) Malvin H. Kalos, Cornell Theory Center; (14) Jeffrey C. Kalb, Maspar Computer Corp.; (15) Edward Masi, Intel; (16) Fred Weingarten, Computing Research Association; (17) David K. Herron, Lilly Research Laboratories; and (18) John B. Gage, Sun Microsystems Laboratories. Subcommittee and committee markups of H.R. 1757, as well as prepared statements from the Consortium for International Earth Science Information Network, International Society for Technology in Education, Coalition for Patent Information Dissemination, and Microcomputer Industry Association, are appended. (KRN)